Clinical Trials Logo

Parkinson Disease clinical trials

View clinical trials related to Parkinson Disease.

Filter by:

NCT ID: NCT00806468 Terminated - Parkinson Disease Clinical Trials

Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease

DEPOPA
Start date: February 2009
Phase: Phase 4
Study type: Interventional

This study will be conducted to study the effect of Desmopressin on the nocturnal micturition frequency in patients with idiopathic Parkinson syndrome.

NCT ID: NCT00804479 Terminated - Parkinson's Disease Clinical Trials

The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)

CALM-PD Cohort
Start date: January 2002
Phase: N/A
Study type: Observational

To determine the long-term consequences (8 years) of initiating patients with Parkinson's disease on either pramipexole or levodopa. We hypothesize that patients initiating therapy with pramipexole compared with levodopa will demonstrate less self-reported disability as measured by the Modified Schwab and England (S/E) scale 8 years after randomization.

NCT ID: NCT00802191 Terminated - Parkinson Disease Clinical Trials

WiiMote Game Controller as a Device to Study Movement Disorders

Start date: August 2007
Phase: N/A
Study type: Observational

Purpose of the study: The purpose of this study is to investigate the Wii remote game control device for use in the study of Movement Disorders. The term "Movement Disorders" refers to a group of abnormal medical conditions characterized by involuntary body movements. Current treatment of these disorders is primarily geared to improve symptoms. Rating scales are usually used to grade response to treatment. These rating scales require special training, take a lot of time, and often present with great variability. Thus, the development of a simple device to perform efficacy measurements offers a great advantage over current methods and is less costly.

NCT ID: NCT00794313 Terminated - Parkinson's Disease Clinical Trials

Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease

Start date: September 2009
Phase: N/A
Study type: Interventional

Levodopa is the main drug treatment for Parkinson's disease. Levodopa can cause unwanted and uncontrolled movements called dyskinesias. A drug called amantadine can reduce these movements. To date, there are no objective measures of these movements. The purpose of this study is to measure the reduction of the movements by amantadine and/or topiramate using an objective measure.

NCT ID: NCT00762814 Terminated - Parkinson Disease Clinical Trials

The Use of Sensory or Motor Cues Using Electrical Stimulation to Reduce Gait Freezing in Patients With Parkinson Disease

Start date: May 2008
Phase: Early Phase 1
Study type: Interventional

Some individuals with Parkinson disease experience "freezing" during walking which results in their inability to move their feet. They often have difficulty starting to move once they have stopped. Freezing often results in loss of balance and falling. Oral medications for Parkinson disease aren't as effective in treating freezing as it is in reducing other symptoms. Another treatment for freezing is instruction in walking using visual targets or auditory cues (thinking of a rhythm or beat). These cues can be initially effective for some individuals, but the effects do not last. Other types of cues have not been studied. We want to examine the effects of two other cues, tactile (touch) or motor (muscle contraction), on the effects of freezing.

NCT ID: NCT00761436 Terminated - Clinical trials for Parkinson''s Disease

Pilot Study of Safety and Efficacy of Spheramine

Start date: February 29, 2000
Phase: Phase 2
Study type: Interventional

Tolerability and Efficacy of Spheramine will be evaluated after operative implantation (Stereotactic Intrastriatal Implantation) in patients with advanced Parkinson's Disease

NCT ID: NCT00740714 Terminated - Parkinson Disease Clinical Trials

Effects of Coenzyme Q10 (CoQ) in Parkinson Disease

QE3
Start date: December 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of high dosages of Coenzyme Q10 in slowing clinical decline in people who have early Parkinson disease.

NCT ID: NCT00669461 Terminated - Parkinson's Disease Clinical Trials

Lubiprostone as a Treatment for Constipation in Parkinson's Disease

Start date: June 2009
Phase: N/A
Study type: Interventional

Delayed colonic transient time secondary to a multi-degenerative process is the most likely cause of constipation in idiopathic PD. Since lubiprostone demonstrated its ability to accelerate colonic transit time in healthy volunteers in addition to activating the chloride channels in the intestinal cells, it has the potential to improve constipation in patients with PD with no subsequent adverse events on the control of the neurological manifestation of PD. So we hypothesize the following: 1. Lubiprostone will improve ratings on the Bristol stool form scale (BSFS) in patients with PD induced constipation compared to baseline.(primary) 2. Lubiprostone will increase the number of spontaneous bowel movements (SBM) per week, compared to baseline. (secondary) 3. Lubiprostone will improve health related quality of life in subjects with PD induced constipation. ( secondary)

NCT ID: NCT00664209 Terminated - Parkinson's Disease Clinical Trials

Treating H. Pylori in Parkinson's Patients With Motor Fluctuations

Start date: January 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether treatment of H. pylori (an infection of the stomach) improves treatment effectiveness in patients with Parkinson's disease and motor fluctuations.

NCT ID: NCT00663312 Terminated - Clinical trials for Idiopathic Parkinson's Disease

Impact of Deep Brain Stimulation of Subthalamic Nucleus on the Hepatic Glucose Production in Parkinson's Disease

Start date: April 2008
Phase: N/A
Study type: Interventional

Parkinson' disease is a neurodegenerative disorder characterised by bradykinesia, rigidity, rest tremor and postural instability. Dopaminergic therapy such as L-Dopa and dopamine agonists usually leads to a dramatic improvement of symptoms, but disease progression nevertheless remains inevitable. Bilateral Deep brain stimulation in subthalamic nucleus (STN) leads to a spectacular clinical improvement in patients with motor complications and is now considered as the gold standard surgical treatment. However, this surgery induces a post-operative body weight gain which may limit the benefits of this technique and induce critical metabolic disorders such as profound alterations in the central control of energy metabolism. Previous data seems to show that glucose metabolism is also altered. The aim of this prospective study was to identify if the STN stimulation could modify glucose metabolism regulation especially the endogen glucose production (by liver) Hypothalamus is able to detect glucose concentration variations and to control/adjust glucose levels by modulating the hepatic glucose production. As hypothamus and STN are anatomically closed, we hypothesise that the STN stimulation could modulate the hypothalamus function and consequently modify glucose production.